JAMES WELSH to Neoplasms
This is a "connection" page, showing publications JAMES WELSH has written about Neoplasms.
Connection Strength
2.242
-
Is Single-Site Radiation Therapy Enough to Augment the Immune System and Enhance Immunotherapy for Metastatic Disease? Semin Radiat Oncol. 2024 Jul; 34(3):272-275.
Score: 0.149
-
Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):676-683.
Score: 0.131
-
Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol. 2021 07; 31(3):217-226.
Score: 0.121
-
Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Front Immunol. 2020; 11:573326.
Score: 0.116
-
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2).
Score: 0.115
-
Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 09 24; 11(1):4840.
Score: 0.115
-
Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):352-364.
Score: 0.114
-
Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):196-203.
Score: 0.110
-
Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019 09 04; 7(1):237.
Score: 0.107
-
Glycosylation and Antitumor Immunity. Int Rev Cell Mol Biol. 2019; 343:111-127.
Score: 0.099
-
Optimizing Radiotherapy with Immunotherapeutic Approaches. Adv Exp Med Biol. 2017; 995:53-71.
Score: 0.089
-
Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
Score: 0.076
-
Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer. 2013 May 15; 119(10):1768-75.
Score: 0.068
-
Dosimetric and clinical review of helical tomotherapy. Expert Rev Anticancer Ther. 2011 Feb; 11(2):309-20.
Score: 0.059
-
Clinical, technical, and basic science progress in helical tomotherapy--the pace continues to accelerate. Technol Cancer Res Treat. 2009 Feb; 8(1):1-2.
Score: 0.051
-
Basics of particle therapy: introduction to hadrons. Am J Clin Oncol. 2008 Oct; 31(5):493-5.
Score: 0.050
-
Clinical implementation of adaptive helical tomotherapy: a unique approach to image-guided intensity modulated radiotherapy. Technol Cancer Res Treat. 2006 Oct; 5(5):465-79.
Score: 0.044
-
Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer. 2024 Oct 09; 12(10).
Score: 0.038
-
The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy. Front Immunol. 2023; 14:1172931.
Score: 0.034
-
Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235.
Score: 0.033
-
Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother Oncol. 2022 12; 177:81-94.
Score: 0.033
-
Helical tomotherapy: an innovative technology and approach to radiation therapy. Technol Cancer Res Treat. 2002 Aug; 1(4):311-6.
Score: 0.033
-
Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Invest. 2022 Feb; 40(2):115-123.
Score: 0.031
-
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. Elife. 2021 11 09; 10.
Score: 0.031
-
Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2022 Jan; 40(1):26-34.
Score: 0.031
-
Financial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials. Int J Cancer. 2021 11 01; 149(9):1683-1690.
Score: 0.030
-
A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nat Biomed Eng. 2021 04; 5(4):297-308.
Score: 0.029
-
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2).
Score: 0.029
-
Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Sci Adv. 2020 05; 6(18):eaay6298.
Score: 0.028
-
Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019 04; 58(4):244-253.
Score: 0.026
-
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol. 2019; 10:193.
Score: 0.026
-
Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther. 2019 03; 195:162-171.
Score: 0.025
-
Letter by Cai et al Regarding Article, "Exposure to Low-Dose Ionizing Radiation From Cardiac Procedures and Malignancy Risk in Adults With Congenital Heart Disease". Circulation. 2018 09 25; 138(13):1377-1378.
Score: 0.025
-
Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clin Cancer Res. 2018 08 01; 24(15):3500-3509.
Score: 0.024
-
Radiation therapy and immunotherapy: what is the optimal timing or sequencing? Immunotherapy. 2018 02 01; 10(4):299-316.
Score: 0.024
-
Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):770-777.
Score: 0.022
-
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J. 2016 Jul-Aug; 22(4):257-66.
Score: 0.021
-
Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 2016 Mar-Apr; 22(2):130-7.
Score: 0.021
-
Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3.
Score: 0.015
-
Hybridizing mechanistic modeling and deep learning for personalized survival prediction after immune checkpoint inhibitor immunotherapy. NPJ Syst Biol Appl. 2024 Aug 14; 10(1):88.
Score: 0.009
-
Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. Immunotherapy. 2018 08; 10(10):851-0.
Score: 0.006